Savara Inc (NASDAQ:SVRA) reported the recent issuance of patent for dry powder vancomycin compositions & related methods by the USPTO. The patent will offer intellectual property protection in the United States for the AeroVanc plan and will expire by 2032.
This gives company vital composition of matter protection for AeroVanc plan in the United States, the leading market for the offering, and is a major component of the firm’s market protection plan which also comprises Qualified Infectious Disease and Orphan Drug Product protection.
Savara has even obtained a Notice of Allowance for AeroVanc. This will serve as authorized communication that the inspection of the patent application has been closed. Once released, the patent will offer protection for its product in Canada until 2032. The firm has parallel patent applications for AeroVanc in distinct phases of prosecution in other major markets across the world.
The prevalence of MRSA pulmonary infection in cystic fibrosis subjects has continued to increase in the U.S., and the infection has been linked with increased use of IV, increased hospitalizations, antibiotics, a faster drop of lung function and shortened life-expectancy. In spite of inhaled antibiotics accessible to CF patients for more than 10 years to cure non-MRSA infections, there exists no authorized inhaled antibiotic for the cure of MRSA in CF. Savara’s AeroVanc is being advanced to resolve this unmet medical need in cystic fibrosis.
In a Phase 2 trial in cystic fibrosis subjects with MRSA infection, AeroVanc lessened MRSA density in sputum, as well as demonstrated promising trends of progress in respiratory symptoms and lung function, and prolongation of the time to application of other antibiotics, with encouraging responses in patients aged 21 years or below.
Savara intends to commence a pivotal Phase III trial of AeroVanc for the cure of MRSA in cystic fibrosis patients in Q3 2017.